BIOCARTIS : Oncology diagnostics in times of coronavirus
Biocartis’ recovery path initiated after 1H19 has met an unfortunate pause with the outbreak of the COVID-19 pandemic. While a clear negative impact is to be expected in 2Q20 requiring caution for 1H20 results, we maintain a positive long-term outlook for the company.Biocartis Group NV is a Belgium-based company, which specializes in the development of molecular diagnostic systems, especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.